First Patient Dosed in EVEREST-2 Ph 1 Trial of Novel Mesothelin Logic-Gated CAR T
“Dosing our first patient in this trial is a key step to provide a precise, novel CAR T therapy to patients with solid tumors that express mesothelin with no curative treatment options. Sadly, current treatment options for these patients are palliative and limited by toxicity in the recurrent, unresectable, locally advanced or metastatic setting. All of us at A2 Bio would like to thank participating patients, investigators, and clinical care providers,” said Dr. William Go, chief medical officer of A2 Bio.
Share:
More News
Elevation Oncology today announced that it has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock, plus one non-tradeable contingent value right, which represents the right to receive: (i) 100% of the
“The AMPLITUDE study reinforces the power of a biomarker-driven approach and the potential of this novel combination regimen to shift the treatment paradigm in prostate cancer,” said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “By identifying patients most likely to benefit from
“We are gaining significant momentum on CHM CDH17 and look forward to our interactions with the FDA to get our advanced therapy to patients in need”, said Dr Rebecca McQualter CEO of Chimeric.
“Bringing VVD-214, the only clinical-stage covalent inhibitor of WRN in development worldwide, into our portfolio marks an incredibly exciting moment for Vividion,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “We are eager to progress development of this compound, building on the encouraging clinical data we’ve seen to
